Coya Therapeutics plans to extend treatment beyond 48 weeks for eligible ALSTARS participants receiving COYA 302 for amyotrophic lateral sclerosis. The decision follows completion of targeted enrollment, while randomized efficacy results remain expected in early 2027 and a separate frontotemporal dementia study has been delayed.
Explore how TRexBio’s TRB-071 CD30 agonist and Lilly-partnered TRB-051 could reshape tissue Treg drug development. Read the analysis.
Find out how Antengene’s ATG-207 data could shape autoimmune drug development as CD3 and TGF-beta fusion biology enters focus.
Coya Therapeutics’ COYA 302 fast track status raises the stakes for Treg-based ALS therapy. Find out what comes next.
Atopic dermatitis has more drugs, but not enough durable control. TRexBio’s TRB-061 tests whether tissue Tregs can change that.
Nektar will discuss 52-week REZOLVE-AA data for rezpegaldesleukin on April 20. Find out what the alopecia areata catalyst could mean.
Can LYMPHIR boost CAR-T therapy success in lymphoma? Discover what early trial data reveals about immune microenvironment targeting.
Discover how NImmune Biopharma’s NIM-1324 Phase 2 program could reshape inflammatory bowel disease treatment beyond biologics and JAK inhibitors.
Find out how Kainova Therapeutics’ $32M CAD funding could reshape GPCR-based immuno-oncology and inflammation drug development.
Cellenkos, Inc., a clinical-stage biotechnology company developing allogeneic regulatory T cell (Treg) therapies, has unveiled new data from its investigational product CK0804, presented at the 67th American Society of Hematology (ASH) Annual Meeting. The findings highlight the potential of a dose-intensive regimen of CK0804 to reduce spleen volume, improve symptoms, and lower transfusion dependence in